Clinical trial
Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in…
NCT00077025 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00077025 |
|---|---|
| Title | Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer |
| Official title | Phase II Multicenter, Double-Blind, Randomized Trial Comparing Anastrozole (ZD1033, Arimidex™)-Placebo to the Combination Anastrozole-ZD1839 (Gefitinib, IRESSA™) in Postmenopausal Patients With Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Metastatic Breast Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib, Anastrozole |
| Enrollment | 174 |
| Start date | Jan 1, 2004 |
| Primary completion | May 1, 2013 |
| Completion | May 1, 2013 |
| First posted | Feb 11, 2004 |
| Last update posted | Jul 16, 2014 |
| Countries | Colombia, Mexico, United States, Venezuela |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: